Vitalant

Recent papers from Vitalant

1. RhD-Positive Transfusion in Females of Childbearing Potential in Hemorrhagic Shock: Risk, Reality, and PolicyPrehospital Emergency Care · 2026
2. Red Blood Cell Transfusion Characteristics and Morbidity or Mortality in Very-Low-Birth-Weight InfantsJAMA Network Open · 2026
3. A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM) and paricalcitol as neoadjuvant therapy in pancreatic cancerThe Oncologist · 2026
4. Epidemiology of Pediatric Transfusion ReactionsJAMA Network Open · 2026
5. Caregiver perspectives on disease burden and treatment priorities in KCNT1-related disordersEpilepsy & Behavior · 2026
6. The economic burden of KCNT1-related disorders in the United States: insights from caregiver-reported and EMR-derived dataBMC Health Services Research · 2026
7. CD8 PET imaging with [ ⁸⁹ Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate studyJournal for ImmunoTherapy of Cancer · 2026
8. Multiple consecutive daily therapeutic plasma exchange using exclusively albumin replacement fluid in low bleeding risk patients is associated with only rare and mild bleedsTransfusion · 2026
9. Associations of Blood Donor and Product Characteristics with Platelet Transfusion OutcomesBlood Advances · 2026
10. An Open-Label Phase 1b/2 Trial of Navenibart, a Long-Acting Plasma Kallikrein Inhibitor for Hereditary AngioedemaJournal of Allergy and Clinical Immunology · 2026
11. A low dose is better than no dose: Is it time to consider lowering the US minimum plateletpheresis yield?Transfusion and Apheresis Science · 2026
12. Donidalorsen for Long-Term Prophylaxis of Hereditary Angioedema Attacks: Results from the OASISplus Open-Label Extension Cohort at Year 1Journal of Asthma and Allergy · 2026
13. The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson’s diseaseNature Aging · 2026
14. Transfusion knowledge online: A Wikipedia deep diveVox Sanguinis · 2026
15. Sentinel trends in donor hemoglobin values and low‐hemoglobin deferrals in a large US blood centerTransfusion · 2026
16. Transfusion requirements in recipients of plasma units from blood donors with recent SARS ‐ CoV ‐2 infectionTransfusion · 2026
17. Microbiome-Derived Metabolites Shape CD4⁺ T-Cell Differentiation and Immune Aging in Chronic HIV-1 Infection2026
18. Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III studyBritish Journal of Dermatology · 2025
19. Stem cell collection from peripheral blood of multiple myeloma patientsWorld Journal of Clinical Oncology · 2025
20. Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III studyBritish Journal of Dermatology · 2025